Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic (OTCMKTS:BVNRY) saw a large drop in short interest in April. As of April 30th, there was short interest totaling 3,783 shares, a drop of 60.7% from the April 15th total of 9,626 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 5,552 shares, the short-interest ratio is currently 0.7 days.

Bavarian Nordic Stock Performance

BVNRY stock remained flat at $9.69 during trading on Friday. 219 shares of the company were exchanged, compared to its average volume of 5,165. The business has a fifty day simple moving average of $9.85 and a 200-day simple moving average of $10.06. The firm has a market cap of $2.30 billion, a P/E ratio of 12.75 and a beta of 1.21. Bavarian Nordic has a one year low of $8.11 and a one year high of $13.00.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.37%. The company had revenue of $165.70 million during the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.